Reprogramming Natural Killer Cells for Cancer Immunotherapy

Presented By: Sandro Matosevic, PhD
Speaker Biography: Dr. Sandro Matosevic is an associate professor in the College of Pharmacy at Purdue University, and is a member of the Purdue Center for Cancer Research. Dr. Matosevic runs an NIH-funded research program focused on the development and use of cell-based therapies with natural killer cells and CAR-engineered immune cells in the treatment of cancer and holds a number of patents on the engineering and utilization of NK cells and stem cell-derived NK cells in cancer immunotherapy. ...
Webinar: Reprogramming Natural Killer Cells for Cancer Immunotherapy
Webinar Abstract: Natural killer (NK) cells, immune cells with an innate ability to recognize and eliminate cancer cells, have emerged as attractive effectors in immunotherapy, owing in large part to their ability to target cancers based on MHC ligand mismatch, thus representing a source of potentially allogeneic immune cells, and a safer alternative to T cells. As such, various approaches aimed at exploiting NK cells for immunotherapy have been in development. These approaches have leveraged genetic engineering as a tool to regulate NK cell activation in terms of controlling their anti-tumor function, metabolism and persistence, and have shown promise as anti-cancer therapies. However, targeting complex cancers such as aggressive solid tumors remains a challenge due to profound immunosuppression in the microenvironment of such cancers, which dampens not only NK cell, but also other immune effector responses. In this talk, we discuss opportunities for NK cells in immunotherapy, including novel genetic engineering approaches and therapeutic modulation strategies aimed at enhancing NK cell immune responses, with the ultimate goal to effectively and durably targeting currently uncurable cancers.
Earn PACE Credits:
1. Make sure you’re a registered member of Labroots (www.labroots.c...)
2. Watch the webinar on UA-cam or on the Labroots Website (www.labroots.c...)
3. Click Here to get your PACE credits (Expiration date - October 04, 2025) (www.labroots.c...)
Labroots on Social:
Facebook: / labrootsinc
Twitter: / labroots
LinkedIn: / labroots
Instagram: / labrootsinc
Pinterest: / labroots
SnapChat: labroots_inc

[@isatousarr7044]

Reprogramming Natural Killer (NK) cells for cancer immunotherapy represents a promising frontier in oncology, harnessing the body’s own immune system to target and destroy cancer cells more effectively. Advances in genetic engineering and cell therapy are enhancing the ability of NK cells to recognize and attack cancerous cells while avoiding healthy tissues. However, challenges such as optimizing cell expansion, ensuring persistence in the body, and managing potential off-target effects remain. What innovative strategies could be employed to overcome these hurdles and maximize the therapeutic potential of reprogrammed NK cells in cancer treatment?